BioSpace News Archive

City of Hope, one of the largest cancer research and treatment organizations in the United States and a National Cancer Institute-designated comprehensive cancer Center, and Calidi Biotherapeutics Inc. today jointly announced that the first brain tumor patient was treated at City of Hope.

BridgeBio Pharma, Inc. today announced that on July 10, 2023, the compensation committee of BridgeBio’s board of directors granted eight new employees restricted stock units for an aggregate of 71,250 shares of the Company’s common stock.

Akebia Therapeutics today announced that Akebia completed an End of Dispute Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss Akebia’s forthcoming resubmission of its New Drug Application (NDA) for vadadustat as a treatment for anemia due to chronic kidney disease (CKD) in adult patients on dialysis.

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2023 after the market close on Tuesday, August 1, 2023.

BVI, one of the fastest growing surgical ophthalmic businesses in the world, is proud to announce the opening of its new, state of the art facility in Liège, Belgium.

Eitan Medical, a global leader in advanced infusion therapy and drug delivery solutions with reliable innovations that put patients at the center of care, is pleased to announce the appointment of Shaul Sharoni as the company’s new Chief Financial Officer.

Neumora Therapeutics, Inc. announced the planned initiation of the KOASTAL Program, a Phase 3 pivotal clinical program designed to evaluate the efficacy and safety of navacaprant monotherapy for the treatment of major depressive disorder.

BSF Enterprise PLC, a company focused on unlocking the next generation of biotechnological solutions using cell-based tissue engineering, provides a commercial update on the progress of City-MixTM, the flagship commercial product of its wholly owned subsidiary 3D Bio Tissues.

ACELYRIN, INC., a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, announced the appointment of Ken Lock as Chief Commercial Officer, effectively immediately.

Samsung Biologics, a global contract development and manufacturing organization, released its 2023 Environmental, Social and Governance Report.